Compare Gilead Sciences, Inc. (GILD) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MobilEye Global Inc — how do they compare? Gilead Sciences, Inc. trades at $133.11 (market cap $163.51B), while MobilEye Global Inc trades at $9.07 (market cap $7.94B). The key difference: Gilead Sciences, Inc. is far larger — about 20.6× MobilEye Global Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| GILD | MBLY | |
|---|---|---|
Market Cap | $163.51B | $7.94B |
Sector | Health | Technology |
52-Week High | $155.80 | $16.27 |
52-Week Low | $108.22 | $6.56 |
Enterprise Value | $178.05B | $6.60B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Mobileye (MBLY) trades at $9.06, down 10.21% over 24 hours, reflecting market volatility amid mixed signals. The stock shows a neutral technical stance with key support at $9 and resistance at $10. Fundamentally, the company reported a net loss of -$392M in 2025 despite revenue of $1.89B, with a negative net income margin of -203.97% in 2026 projections. Recent news highlights the planned 2027 U.S. robotaxi launch, signaling strategic expansion beyond its ADAS supplier role.
The outlook hinges on execution of the robotaxi initiative, offering growth potential but carrying significant execution and competitive risks. Analyst consensus is bullish with a $10.71 price target, though profitability challenges and high valuation multiples like EV/EBITDA of 73.31 pose near-term headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
